TGFβR2 aberrant methylation is a potential prognostic marker and therapeutic target in multiple myeloma

International Journal of Cancer

Volumn 125, Issue 8, 2009, Pages 1985-1991

  De Carvalho, Fabrício ^a   Colleoni, Gisele W B ^a   Sampaio Almeida, Manuella S ^a   Carvalho, André L ^b   Vettore, André L ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b BARRETOS CANCER HOSPITAL   (Brazil)

Author keywords

Methylation; Multiple myeloma; Prognosis; Therapy

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYCLIN DEPENDENT KINASE INHIBITOR 2B; DEXAMETHASONE; DOXORUBICIN; GLUTATHIONE TRANSFERASE P1; IMMUNOGLOBULIN A; MELPHALAN; PREDNISONE; SUPPRESSOR OF CYTOKINE SIGNALING 1; THALIDOMIDE; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2; UVOMORULIN; VINCRISTINE; PROTEIN SERINE THREONINE KINASE; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRANSFORMING GROWTH FACTOR BETA TYPE II RECEPTOR; TRANSFORMING GROWTH FACTOR-BETA TYPE II RECEPTOR; TUMOR PROTEIN;

ADULT; AGED; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE MARKER; FEMALE; GENE MUTATION; GENETIC ANALYSIS; HUMAN; MALE; METHYLATION; MULTIPLE MYELOMA; MULTIVARIATE ANALYSIS; ONCOGENE; OUTCOME ASSESSMENT; PATHOLOGY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; DNA METHYLATION; GENETICS; MIDDLE AGED; PROMOTER REGION; SURVIVAL RATE;

ADULT; AGED; AGED, 80 AND OVER; DNA METHYLATION; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM PROTEINS; POLYMERASE CHAIN REACTION; PROGNOSIS; PROMOTER REGIONS, GENETIC; PROTEIN-SERINE-THREONINE KINASES; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SURVIVAL RATE;

EID: 70349263849     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.24431     Document Type: Article

References (52)

1. Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med 2004;351:1860-1873
2. Hallek M, Bergsagel PL, Anderson KC. Multiple myeloma: increasing evidence for a multistep transformation process. Blood 1998;91:3-21. (Pubitemid 28018724)
3. Kastrinakis NG, Gorgoulis VG, Foukas PG, Dimopoulos MA, Kittas C. Molecular aspects of multiple myeloma. Ann Oncol 2000;11:1217-1228
4. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003;349:2042-2054 (Pubitemid 37448928)
5. Geiman TM, Robertson KD. Chromatin remodeling, histone modifications, and DNA methylation-how does it all fit together? J Cell Biochem 2002;87:117-125
6. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002;3:415-428
7. Costello JF, Fruhwald MC, Smiraglia DJ, Rush LJ, Robertson GP, Gao X, Wright FA, Feramisco JD, Peltomaki P, Lang JC, Schuller DE, Yu L, et al. Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nat Genet 2000;24:132-138 (Pubitemid 30094712)
8. Esteller M, Corn PG, Baylin SB, Herman JG. A gene hypermethylation profile of human cancer. Cancer Res 2001;61:3225-3229 (Pubitemid 32695003)
9. Galm O, Wilop S, Reichelt J, Jost E, Gehbauer G, Herman JG, Osieka R. DNA methylation changes in multiple myeloma. Leukemia 2004;18:1687-1692 (Pubitemid 39386348)
10. Chim CS, Liang R, Fung TK, Choi CL, Kwong YL. Epigenetic dysregulation of the death-associated protein kinase/p14/HDM2/p53/Apaf-1 apoptosis pathway in multiple myeloma. J Clin Pathol 2007;60:664-669 (Pubitemid 46975222)
11. Chim CS, Kwong YL, Fung TK, Liang R Methylation profiling in multiple myeloma. Leuk Res 2004;28:379-385 (Pubitemid 38199946)
12. Takahashi T, Shivapurkar N, Reddy J, Shigematsu H, Miyajima K, Suzuki M, Toyooka S, Zochbauer-Muller S, Drach J, Parikh G, Zheng Y, Feng Z, et al. DNA methylation profiles of lymphoid and hematopoietic malignancies. Clin Cancer Res 2004;10:2928-2935 (Pubitemid 38619667)
13. Song YF, Xu R, Zhang XH, Chen BB, Chen Q, Chen YM, Xie Y. High-frequency promoter hypermethylation of the deleted in liver cancer-1 gene in multiple myeloma. J Clin Pathol 2006;59:947-951 (Pubitemid 44422849)
14. Seidl S, Ackermann J, Kaufmann H, Keck A, Nosslinger T, Zielinski CC, Drach J, Zochbauer-Muller S. DNA-methylation analysis identifies the E-cadherin gene as a potential marker of disease progression in patients with monoclonal gammopathies. Cancer 2004;100:2598-2606 (Pubitemid 38715765)
15. Gonzalez-Paz N, Chng WJ, McClure RF, Blood E, Oken MM, Van NB, James CD, Kurtin PJ, Henderson K, Ahmann GJ, Gertz M, Lacy M, et al. Tumor suppressor p16 methylation in multiple myeloma: biological and clinical implications. Blood 2007;109:1228-1232 (Pubitemid 46220672)
16. Ribas C, Colleoni GW, Felix RS, Regis Silva MR, Caballero OL, Brait M, Bordin JO. p16 gene methylation lacks correlation with angiogenesis and prognosis in multiple myeloma. Cancer Lett 2005;222:247-254 (Pubitemid 40603652)
17. Kyle RA, Clild JA, Anderson K, Barlogie B, Bataille R, Bensinger W, Blade J, Boccadoro M, Dalton W, Dimopoulos M, Djulbegovic B, Drayson M, et al. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003;121:749-757 (Pubitemid 36718191)
18. Greipp PR, San MJ, Durie BG, Crowley JJ, Barlogie B, Blade J, Boccadoro M, Child JA, vet-Loiseau H, Kyle RA, Lahuerta JJ, Ludwig H, et al. International staging system for multiple myeloma. J Clin Oncol 2005;23:3412-3420 (Pubitemid 46300270)
19. Vidal DO, Paixao VA, Brait M, Souto EX, Caballero OL, Lopes LF, Vettore AL. Aberrant methylation in pediatric myelodysplastic syndrome. Leuk Res 2007;31:175-181 (Pubitemid 44883192)
20. Brabender J, Usadel H, Danenberg KD, Metzger R, Schneider PM, Lord RV, Wickramasinghe K, Lum CE, Park J, Salonga D, Singer J, Sidransky D, et al. Adenomatous polyposis coli gene promoter hypermethylation in non-small cell lung cancer is associated with survival. Oncogene 2001:20:3528-3532 (Pubitemid 32619405)
21. Kuehl WM, Bergsagel PL. Multiple myeloma: evolving genetic events and host interactions. Nat Rev Cancer 2002;2:175-187
22. Lo YM, Wong IH, Zhang J, Tein MS, Ng MH, Hjelm NM. Quantitative analysis of aberrant p16 methylation using real-time quantitative methylation-specific polymerase chain reaction. Cancer Res 1999;59:3899-3903 (Pubitemid 29393548)
23. Eads CA, Danenberg KD, Kawakami K, Saltz LB, Blake C, Shibata D, Danenberg PV, Laird PW. MethyLight: a high-throughput assay to measure DNA methylation. Nucleic Acids Res 2000;28:E32.
24. Ng SS, Tsao MS, Nicklee T, Hedley DW. Wortmannin inhibits pkb/akt phosphorylation and promotes gemcitabine antitumor activity in orthotopic human pancreatic cancer xenografts in immunodeficient mice. Clin Cancer Res 2001;7:3269-3275 (Pubitemid 32963853)
25. Tasaka T, Asou H, Munker R, Said JW, Berenson J, Vescio RA, Nagai M, Takahara J, Koeffler HP. Methylation of the p16INK4A gene in multiple myeloma. Br J Haematol 1998;101(3):558-564 (Pubitemid 28266953)
26. Gonzalez M, Mateos MV, Garcia-Sanz R, Balanzategui A, Lopez- Perez R, Chillon MC, Gonzalez D, Alaejos I, San Miguel JF. De novo methylation of tumor suppressor gene p16/INK4a is a frequent finding in multiple myeloma patients at diagnosis. Leukemia 2000;14:183-187 (Pubitemid 30068390)
27. Guillerm G, Gyan E, Wolowiec D, Facon T, vet-Loiseau H, Kuliczkowski K, Bauters F, Fenaux P, Quesnel B. p16(INK4a) and p15(INK4b) gene methylations in plasma cells from monoclonal gammopathy of undetermined significance. Blood 2001;98:244-246
28. Martin P, Santon A, Garcia-Cosio M, Bellas C. hMLH1 and MGMT inactivation as a mechanism of tumorigenesis in monoclonal gammopathies. Mod Pathol 2006;19:914-921 (Pubitemid 43910470)
29. Dib A, Barlogie B, Shaughnessy JD, Jr, Kuehl WM. Methylation and expression of the p16INK4A tumor suppressor gene in multiple myeloma. Blood 2007;109:1337-1338 (Pubitemid 46220692)
30. Mateos MV, Garcia-Sanz R, Lopez-Perez R, Moro MJ, Ocio E, Hernandez J, Megido M, Caballero MD, Fernandez-Calvo J, Barez A, Almeida J, Orfao A, et al. Methylation is an inactivating mechanism of the p16 gene in multiple myeloma associated with high plasma cell proliferation and short survival. Br J Haematol 2002;118:1034-1040 (Pubitemid 35025966)
31. Guillerm G, Depil S, Wolowiec D, Quesnel B Different prognostic values of p15(INK4b) and p16(INK4a) gene methylations in multiple myeloma. Haematologica 2003;88:476-478 (Pubitemid 36547138)
32. Elliott RL, Blobe GC. Role of transforming growth factor Beta in human cancer. J Clin Oncol 2005;23:2078-2093 (Pubitemid 46211385)
33. Kehrl JH, Roberts AB, Wakefield LM, Jakowlew S, Sporn MB, Fauci AS. Transforming growth factor beta is an important immunomodulatory protein for human B lymphocytes. J Immunol 1986;137:3855-3860
34. Dong M, Blobe GC. Role of transforming growth factor-beta in hematologic malignancies. Blood 2006;107:4589-4596 (Pubitemid 43882602)
35. Urashima M, Ogata A, Chauhan D, Hatziyanni M, Vidriales MB, Dedera DA, Schlossman RL, Anderson KC. Transforming growth factor- beta1: differential effects on multiple myeloma versus normal B cells. Blood 1996;87:1928-1938 (Pubitemid 26068909)
36. Amoroso SR, Huang N, Roberts AB, Potter M, Letterio JJ. Consistent loss of functional transforming growth factor beta receptor expression in murine plasmacytomas. Proc Natl Acad Sci USA 1998;95:189-194 (Pubitemid 28103929)
37. Fearon ER, Cho KR, Nigro JM, Kern SE, Simons JW, Ruppert JM, Hamilton SR, Preisinger AC, Thomas G, Kinzler KW. Identification of a chromosome 18q gene that is altered in colorectal cancers. Science 1990;247:49-56. (Pubitemid 20059936)
38. Lawlor KG, Narayanan R. Persistent expression of the tumor suppressor gene DCC is essential for neuronal differentiation. Cell Growth Differ 1992;3:609-616
39. Hedrick L, Cho KR, Fearon ER, Wu TC, Kinzler KW, Vogelstein B. The DCC gene product in cellular differentiation and colorectal tumorigenesis. Genes Dev 1994;8:1174-1183 (Pubitemid 24163445)
40. Uchino S, Tsuda H, Noguchi M, Yokota J, Terada M, Saito T, Kobayashi M, Sugimura T, Hirohashi S. Frequent loss of heterozygosity at the DCC locus in gastric cancer. Cancer Res 1992;52:3099-3102
41. Hohne MW, Halatsch ME, Kahl GF, Weinel RJ. Frequent loss of expression of the potential tumor suppressor gene DCC in ductal pancreatic adenocarcinoma. Cancer Res 1992;52:2616-2619
42. Pearlstein RP, Benninger MS, Carey TE, Zarbo RJ, Torres FX, Rybicki BA, Dyke DL. Loss of 18q predicts poor survival of patients with squamous cell carcinoma of the head and neck. Genes Chromosomes Cancer 1998;21:333-339 (Pubitemid 28165041)
43. Ho KY, Kalle WH, Lo TH, Lam WY, Tang CM. Reduced expression of APC and DCC gene protein in breast cancer. Histopathology 1999;35:249-256 (Pubitemid 29468959)
44. Inokuchi K, Miyake K, Takahashi H, Dan K, Nomura T. DCC protein expression in hematopoietic cell populations and its relation to leukemogenesis. J Clin Invest 1996;97:852-857 (Pubitemid 26057105)
45. Porfiri E. DCC (deleted in colorectal cancer) inactivation in hematological malignancies. Leuk Lymphoma 1995;18:69-72.
46. Kato H, Zhou Y, Asanoma K, Kondo H, Yoshikawa Y, Watanabe K, Matsuda T, Wake N, Barrett JC. Suppressed tumorigenicity of human endometrial cancer cells by the restored expression of the DCC gene. Br J Cancer 2000;82:459-466 (Pubitemid 30045398)
47. Forcet C, Ye X, Granger L, Corset V, Shin H, Bredesen DE, Mehlen P. The dependence receptor DCC (deleted in colorectal cancer) defines an alternative mechanism for caspase activation. Proc Natl Acad Sci U S A 2001;98:3416-3421 (Pubitemid 32220860)
48. Chen YQ, Hsieh JT, Yao F, Fang B, Pong RC, Cipriano SC, Krepulat F. Induction of apoptosis and G2/M cell cycle arrest by DCC. Oncogene 1999;18:2747-2754 (Pubitemid 29237663)
49. Inokuchi K, Yamaguchi H, Hanawa H, Tanosaki S, Nakamura K, Tarusawa M, Miyake K, Shimada T, Dan K. Loss of DCC gene expression is of prognostic importance in acute myelogenous leukemia. Clin Cancer Res 2002;8:1882-1888 (Pubitemid 34633750)
50. de LM, Ravandi F, Shahjahan M, Andersson B, Couriel D, Donato M, Khouri I, Gajewski J, van BK, Champlin R, Giralt S, Kantarjian H. Long-term follow-up of a phase I study of high-dose decitabine, busulfan, and cyclophosphamide plus allogeneic transplantation for the treatment of patients with leukemias. Cancer 2003;97:1242-1247 (Pubitemid 36237310)
51. Shaker S, Bernstein M, Momparler LF, Momparler RL. Preclinical evaluation of antineoplastic activity of inhibitors of DNA methylation (5-aza-20-deoxycytidine) and histone deacetylation (trichostatin A, depsipeptide) in combination against myeloid leukemic cells. Leuk Res 2003;27:437-444 (Pubitemid 36287205)
52. Kavsak P, Rasmussen RK, Causing CG, Bonni S, Zhu H, Thomsen GH, Wrana JL. Smad7 binds to Smurf2 to form an E3 ubiquitin ligase that targets the TGF beta receptor for degradation. Mol Cell 2000;6:1365-1375 (Pubitemid 32045929)